Official ESCRS | European Society of Cataract & Refractive Surgeons
Athens 2016 Registration Programme Exhibitor Information Virtual Exhibition Satellite Meetings
ATHENS escrs


Search Abstracts by author or title
(results will display both Free Papers & Poster)

Laser photocoagulation and bevacizumab for recurrent pterygium: a new approach

Poster Details

First Author: E.Mata Diaz SPAIN

Co Author(s):    C. Monton Gimenez   B. Jimenez-Rolando   E. Conesa Hernandez   A. Sanchez-Ventosa   C. de Pablo Martin  

Abstract Details


To assess the efficacy and safety of a combined therapy: LASER photocoagulation and topical bevacizumab in recurrent pterygium.


Department of Ophthalmology .Hospital de Cruz Roja San Jose y Santa Adela.Madrid. Spain


A 45 years old woman presented pterygium recurrence 3 months after surgical excision with autograft fixed with Tissucol. Recurrence from the inferior edge of the graft advanced 1,5 mm onto cornea with 1,5mm width at the limbus. After informed consent we performed photocoagulaciĆ³n with argon LASER in the limbar zone of the recurrence. A modification of Caldwell technique with a triple row of confluent impacts (size: 500micras and power :400watts )was performed. Topical treatment with bevacizumab 1% (10mg/ml) 4 times a day was scheduled during 1 month. The patient was followed 1 year.


After one month no changes were observed in the pterygium recurrence so treatment was discontinued. The patient was observed monthly in order to detect further growth. A month later the recurrence began to regress ,vessel diameter and corneal growth were stopped at the limbar edge. There was only a conjunctival fold at the recurrence area 1 year later. No side effects were observed.


Combined therapy: Argon laser photocoagulation +topical bevacizumab seems to be a good and safe approach of pterygium recurrence. FINANCIAL DISCLOUSRE: NONE

Back to Poster listing